2 February 2021 - Wits University
Researchers at the University of Oxford have today published in Preprints with The Lancet an analysis of further data from the ongoing trials of the vaccine.
The Vaccines and Infectious Diseases Analytics Research Unit (VIDA) at Wits University runs the South African Oxford Covid-19 vaccine trial. Professor Shabir Madhi, Executive Director of Wits VIDA and Dean of the Faculty of Health Sciences at the University, leads these trials and he is a co-author in the Preprints.
In releasing the data regarding sustained protection of 76% during the 3-month interval until the second dose, scientists at Oxford reveal that the vaccine efficacy is higher at longer prime-boost intervals, and that a single dose of the vaccine is 76% effective from 22- to up to 90-days post vaccination. The analyses reveal:
The Oxford/AstraZeneca vaccine that South Africa received last week might not be effective against the more common 501Y.V2 variant that is spreading locally and globally.
Dan Merino: Hello and welcome to the first episode of a new podcast from The Conversation!
Gemma Ware: Each week we’ll be bringing you expert analysis on the world’s biggest stories
Dan: And groundbreaking new research, explained by the academics behind it.
In this episode, we’re talking to three experts about the three separate Mars missions due to arrive on the red planet in February.
Jim Bell: What we’re looking for is evidence of past life.
Gemma: We’ll also hear from a researcher who has just carried out a rare survey of public opinion in Belarus, more than six months into protests there over a disputed election.
COVID19 News - Oxford Covid-19 vaccine shows sustained protection of 76% during 3-month interval until second dose wits.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wits.ac.za Daily Mail and Mail on Sunday newspapers.